Quarterly ResultAug 7, 2026, 04:43 PM
AIM ImmunoTech Q2 Net Loss $3.79M; Cash $9.9M; Regains NYSE Compliance
AI Summary
AIM ImmunoTech reported a net loss of $3.79 million for the second quarter of 2026, an increase from $2.79 million in the prior year. Despite the increased loss, the company significantly improved its financial position, with cash and cash equivalents rising to $9.9 million and stockholders' equity turning positive to $7.74 million. The company also successfully regained compliance with NYSE American listing requirements. Operationally, progress continues on the DURIPANC Phase 2 clinical study for Ampligen in pancreatic cancer, with all subjects enrolled and detailed data anticipated later this year, alongside plans for a Phase 3 trial.
Key Highlights
- Net loss for the three months ended June 30, 2026, was $3.79 million, compared to $2.79 million in Q2 2025.
- Cash and cash equivalents increased to $9.9 million at June 30, 2026, from $2.985 million at December 31, 2025.
- Total stockholders' equity turned positive to $7.74 million from a $9.78 million deficit at December 31, 2025.
- Total liabilities decreased to $4.99 million at June 30, 2026, from $15.57 million at December 31, 2025.
- AIM ImmunoTech regained compliance with NYSE American listing standards on June 12, 2026.
- All subjects enrolled in the DURIPANC Phase 2 study for Ampligen in pancreatic cancer; data expected later this year.
- Company engaged Thermo Fisher Scientific to design anticipated Phase 3 clinical trial for Ampligen.
Price Impact
More from AIM